Medipal Holdings Corp.
www.medipal.co.jp
Latest From Medipal Holdings Corp.
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
Asian Investors Bankroll €40m Promethera Biosciences Series D
Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.
Takeda Poised To Move Into Pharma Top 10 With Shire Combination
Takeda is clearly keen on Shire's rare disease therapies, but the future of the ophthalmology business, and notably the dry eye drug Xiidra, is less certain. The shutters may close on Shire's headquarters in Ireland as well.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Services
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Medipal Holdings Corp.
- Senior Management
- Shuichi Watanabe, Pres. & CEO
- Contact Info
-
Medipal Holdings Corp.
Phone: 3 3517 5800
2-7-15, Yaeju, Chuo-ku
Tokyo, 104-8461
Japan